Revised Curaleaf offer puts Aurora's standalone plan under scrutiny

Aurora Cannabis Inc. (TSX:ACB) is in the spotlight because it is defending against a hostile take-over bid from Curaleaf Holdings, Inc., which was revised in early October to an offer that Curaleaf values at US$5.00 per Aurora share. Aurora's board had said it would give a formal recommendation on the revised terms after its special committee reviews them. In the meantime it has told shareholders to take no action. The company's case for independence rests on a debt-free balance sheet, a growing international medical cannabis business and EU-GMP certified production capacity.

Aurora's common shares trade on the Toronto Stock Exchange and on Nasdaq, both under the symbol ACB. Based in Edmonton, Alberta, it serves medical cannabis markets in Canada and abroad, with Germany the most prominent. Miguel Martin is Executive Chairman and Chief Executive Officer.

Listing context

S&P Dow Jones Indices removed the company from the S&P/TSX Composite Index in a quarterly review in September 2022.

How the contest with Curaleaf has unfolded

Curaleaf announced its bid on 11 August 2026 and formally started it on 18 August. The original terms offered US$0.75 in cash plus 0.3463 of a Curaleaf subordinate voting share for each Aurora share. The total value was capped at US$5.00, and the implied value at the base exchange ratio was about US$4.00.

In a Directors' Circular dated 1 September 2026, Aurora's board unanimously recommended that shareholders reject the bid by not tendering. The board cited a fairness opinion from Fort Capital, which found the consideration inadequate from a financial point of view. The board also argued that roughly 80 per cent of the value would come in Curaleaf shares. It also pointed to Curaleaf's debt of around US$1.1 billion and the limited voting power Aurora holders would have in a combined company.

The dispute has also moved into regulatory filings. On 2 September Aurora complained to the Alberta Securities Commission about what it called deficiencies in the bid. In a release dated 14 September, it pushed back against Curaleaf's application to stop Aurora's at-the-market share programme. Aurora said the programme predated the bid and had been inactive for several weeks.

On 6 October Aurora responded to Curaleaf's notice of variation. The revised consideration is 0.4013 of a Curaleaf subordinate voting share plus US$1.00 in cash per Aurora share, which Curaleaf values at US$5.00. The expiry has moved to 4 December 2026. Aurora has not yet given a recommendation on these revised terms.

First-quarter fiscal 2027 results

Aurora's most recent reported results cover the first quarter of fiscal 2027, the three months to 30 June 2026. They were released on 5 August 2026 and are stated in Canadian dollars. Net revenue fell 9 per cent year on year to $67.6 million. Medical cannabis revenue was almost unchanged at $64.0 million, but its mix shifted. International medical sales rose 17 per cent to $43.3 million, led by Germany. Canadian medical revenue fell 25 per cent to $20.7 million, which the company linked mainly to changes to federal reimbursement rates effective 1 April 2026.

Profitability weakened on several adjusted measures. Adjusted gross margin before fair value adjustments was 58 per cent, down from 64 per cent, and adjusted EBITDA fell to $3.4 million from $10.8 million. The net loss from continuing operations narrowed to $4.0 million from $10.2 million. Free cash flow was negative at $5.8 million, compared with a positive $6.8 million a year earlier. Management kept its fiscal 2027 outlook unchanged and said it expected second-quarter revenue and adjusted EBITDA to rise from the first-quarter levels.

Portfolio reshaping and industry drivers

Aurora has narrowed its focus to global medical cannabis. It sold its 50.1 per cent stake in Bevo Agtech on 17 February 2026, and Bevo is now reported as a discontinued operation. It is also leaving the lower-margin Canadian consumer and plant propagation businesses. On 14 April 2026 it closed the acquisition of Safari Flower Company, which added an EU-GMP certified indoor cultivation and manufacturing facility of about 59,000 square feet. In July Aurora said the Ontario site had received a three-year EU-GMP certification.

Industry conditions explain much of this strategy. European medical markets, Germany in particular, have become the main source of growth for Canadian licensed producers with EU-GMP capacity. The crowded adult-use market offers thinner margins.

Balance sheet, funding and dividends

At 30 June 2026 Aurora reported cash, cash equivalents including restricted cash, and short-term investments of $149.1 million. It said it had no debt and reported working capital of $320.0 million. That balance sheet is central to its defence: Aurora argues that a leveraged Curaleaf is seeking access to its cash.

Aurora does not pay a dividend. The at-the-market programme remains a possible, though recently inactive, source of equity funding. No valuation is attempted here.

Risks and upcoming milestones

The immediate uncertainty is how the take-over contest ends, whether through rejection, further revisions, a competing proposal or regulatory rulings. On the operating side, the risks include continued pressure on Canadian medical reimbursement, reliance on German and other international regulation, currency movements, execution risk in integrating Safari Flower and closing down legacy segments, and recent negative free cash flow. Using the at-the-market programme would dilute existing holders.

The upcoming milestones are clear. The board's recommendation on the revised bid is expected in a news release and an updated Directors' Circular. The revised offer expires on 4 December 2026 unless it is extended or withdrawn. Second-quarter fiscal 2027 results, for the period to 30 September, should show whether management's expected sequential improvement has happened. Until then, the evidence points to a well-funded company with a growing international business, set against weaker margins and an unresolved contest for control.